Abstract Patients with rheumatoid arthritis (RA) suffer an increased burden of infectious disease-related morbidity and mortality and have twice the risk of acquiring a severe infection compared to the general population. This increased risk is not only a result of the autoimmune disease but is also attributed to the immunosuppressive therapies that are commonly used in this patient population. Given the increase in infectionrelated risks in RA, there is great interest in mitigating such risk. A number of vaccines are available to the rheumatologist, with a handful that are of importance for RA patients in the United States. The goal of this paper is to highlight the most recent literature on the key vaccines and the specific considerations for the rheumatologist and their RA patients, with a particular focus on influenza, pneumococcal, and herpes zoster vaccines. It is important for rheumatologist to understand and be aware of which vaccines are live and what potential contraindications exist for giving vaccines to RA patients.
The 2012 ACR vaccine recommendations (Table 1) state that the optimal time for administering vaccines (e.g., influenza, pneumococcal, HPV, others) is prior to starting a non-biologic or biologic DMARD [6] . In general, this helps optimize host vaccine responses, and, in the case of live vaccines like herpes zoster vaccine, limits the theoretical risk of local or disseminated infection in an immunosuppressed patients taking a biologic [6] . More detailed information about each of the vaccinations most relevant for adult RA patients in the U.S. are described in this review, with a particular focus on the extent to which biologics and nonbiologic DMARDs could affect vaccine effectiveness.
Key Vaccines and Specific Considerations for Rheumatologist and their RA Patients

Influenza
Overview and Recommendations
The constituents of the seasonal influenza vaccine potentially change on a yearly basis according to surveillance data regarding the most prevalent circulating influenza strain.
Starting in 2009, the pandemic H1N1 strain was incorporated into the basic constituents of the trivalent seasonal vaccine; two influenza A antigens along with an influenza B component(s). In the United States, as of 2013, a quadravalent and trivalent vaccine became available in killed formulations (intramuscular) and the trivalent vaccine is also available as a live formulation (nasal). It is anticipated that the quadrivalent will gradually replace the trivalent vaccine in the next few years. The live vaccine is approved in only healthy individuals aged 2-49 years and is contraindicated for those with rheumatic disease [7, 8] . For the treating rheumatologist, only intramuscular attenuated influenza vaccine formulations should be administered on an annual basis [6, 8] . In patients with an anaphylactic reaction to eggs, a recombinant influenza vaccine is available and can be used as it lacks ovalbulmin [8] .
Effect of DMARDs and Biologics on Vaccine Effectiveness
A total of 16 studies in RA have been published that describe use of the influenza vaccine and its immunologic effectiveness, with the potential for heterogeneity noted given that the serotypes covered can vary from year to year. Influenza vaccine studies within this population typically focus on the h According to the RAND/UCLA Appropriateness Method, panel members judge it as "not appropriate" and therefore it qualifies as "recommended" (median score on appropriates scale was 1) immunogenicity of the vaccine as a proxy for clinical effectiveness by evaluating surrogate measures of protection such as the geometric mean titer (GMT) of hemaglutinin inhibition (HI) antibodies. HI titers of 1:40 or greater have been shown to be protective against influenza in the general population [9] . Most of the studies evaluated suggest that RA patients using methotrexate and/or anti-TNF therapy (adalimumab, etanercept, infliximab) achieve an acceptable humoral response, although their response is lower than in healthy controls [10•, 11, 12•, 13-18] . A recent study, in 2012, involving RA patients receiving tocilizumab, methotrexate (MTX) or the combination of the two suggest that there was no decreased effects of TCZ, and post-vaccination GMTs increased significantly for all strains of the influenza vaccine [19•] . Abatacept, on the other hand, has been shown to significantly reduce the humoral response to pandemic 2009 influenza A/H1N1 vaccine in RA patients compared to patients with RA on methotrexate and healthy controls, although this study did not evaluate tri-or quadrivalent vaccine [12•, 20] . Rituximab severely reduces the responsiveness of the influenza vaccine in patients with RA as shown in several studies, and, not surprisingly, this reduction in response is dependent upon the timing of the vaccine in relation to rituximab administration [21, 22•, 23, 24] . Supporting data for this assertion includes one study showing that pre-rituximab treated patients had a greater response to the influenza vaccine than those in the post-rituximab treatment group [22•] , while another study showed that patients vaccinated 6-10 months after rituximab had a better response that those vaccinated 4-8 weeks after rituximab [23] . It was also found that there was no difference in the levels of vaccine-specific Ig between patients treated with rituximab once as compared with those who were treated more than once, suggesting that repeated courses of rituximab induced no cumulative impairment of the vaccine specific response [22•] .
Summary & Recommendation
In summary, the timing of administering the influenza vaccine among patients on immunomodulatory drugs should be straightforward, in that each patient should be vaccinated each fall prior to the advent of the influenza season regardless of their current immunosuppressive regiments, except for rituximab users who were recently treated. For rituxan-treated individuals, waiting as long as possible after treatment would be of benefit, such that clinicians should monitor and be aware of local trends in influenza epidemiology in order to facilitate such decision making. Responses to the influenza vaccine, for the most part, should be adequate no matter what DMARD or biologic regimen is used, except that rituximab severely restricts humoral response to influenza (and other vaccines) when vaccination is given soon after rituximab administration [21, 22•, 23, 24] . 
Herpes Zoster Vaccination
Overview and Recommendations
In order to prevent herpes zoster (HZ), a live-attenuated vaccine (Zostavax) has been developed and is approved for use in individuals age 50 years or older, regardless of varicella history or previous HZ [35] . Currently, the CDC recommends and the ACR endorses that anyone age 60 and older to become vaccinated against HZ [6, 36] . Despite appreciable efficacy in individuals age 50-59, the reasons for the differences between the indication for age 50 and above and the recommendation starting only at age 60 may be related to the greater population health benefit (based upon greater absolute risk reduction) and associated higher cost-effectiveness in older patients. The ACIP and ACR guidelines currently recommend that patients who use methotrexate (<0.4 mg/kg/week, e.g., 25 mg/week), low to moderate doses of glucocorticoids (<20 mg/day prednisone or equivalent) or short-term corticosteroids (<14 days) or intra-articular, bursal, or tenton corticosteroid injections, or azathioprine (<3.0 mg/kg/day) or 6-mercaptopurine (<1.5 mg/kg/day) can receive this vaccination safely [36] . According to ACIP, the HZ vaccine is contraindicated in patients receiving such medications due to theoretical concerns regarding the safety of live vaccine use in patients using biologic therapies such as anti-TNF therapy. Despite the demonstrated efficacy and safety of the zoster vaccine observed in non-RA patients, there are no prospective trials critically examining the clinical efficacy or safety of HZ vaccination in RA patients.
Effect of DMARDs and Biologics on Vaccine Effectiveness
Despite the dearth of prospective trial data of the zoster vaccine in RA, several population-based observational studies have been conducted examining use of the zoster vaccine in patients with RA and other rheumatic diseases (e.g., spondyloarthropathies) [37] . Among a total of 19,326 RA patients older than age 50, only 206 (1 %) received zoster vaccine, suggesting that clinicians may be uncomfortable using the vaccine in patients with rheumatic diseases. Additionally, approximately 60 vaccinated patients in this study were using anti-TNF therapies within 1 month of vaccination, and no cases of HZ were reported during this time frame. A larger study conducted among Medicare beneficiaries in the US identified a larger cohort of patients (n=663) who has been vaccinated while using biologic therapy (most using anti-TNF therapy, predominantly infliximab) and no patients developed zoster or other varicella disease in the 6 weeks after vaccination [38•] . Within this study, only 3.3 % of RA patients, all of whom were age ≥60, received vaccination suggesting this group remains an important target for HZ prevention via vaccination. Moreover, the study suggested a clinical effectiveness and an absolute risk reduction for the vaccine similar to that seen for older patients within the Shingles Prevention Study [39] .
Summary and Recommendations
Although prospective trial data with the live zoster vaccine is essentially non-existent at the present time, a few observational studies shine a positive light towards the future use of HZ vaccine in an RA patient population. The vaccine should be strongly considered for individuals age 50 and older [40] . Given the high risk of HZ in the RA population, approximately double that of healthy older individuals [41•] , it may be warranted to prospectively evaluate the safety and clinical effectiveness of this vaccine in patients using biologic therapy. Additionally, a number of important questions remain about the vaccine, as described below.
Discussion and Evidence Gaps
Recommendations from both the ACR and EULAR highlight the importance and need for vaccination in patients with RA. A number of evidence gaps exist for each of the three major vaccines. For example, the clinical effectiveness of any of these vaccines in an RA population has not been shown prospectively via a controlled trial, and observational data are similarly lacking. In particular, the safety of the herpes zoster vaccine needs to be demonstrated, especially given evidence that patients with RA have high rates of zoster. Additionally, the need for and optimal re-vaccination intervals for pneumococcal vaccination and zoster vaccination is not clear. For example, studies of zoster vaccination conducted in healthy older adults suggest that immunity lasts for up to 5 years [42] , but it is unknown whether this finding can be generalized to RA patients. Finally, despite the availability of these several vaccines, the most effective mechanisms to ensure that at-risk patients receive them have yet to be elucidated. Numerous studies have shown that patients do not receive vaccines as recommended [43] . Despite multiple guidelines, vaccination in the clinical setting is erratic and the need for early efforts through reminder systems such as point of care reminders (paper or electronic medical records) or other health system-related triggers are in their infancy [44] . Another approach would be to delegate a responsible provider or non-physician provider to administer and record all vaccines [45, 46] . More direct engagement of patients, rather than solely relying on their healthcare providers, may be fruitful to improve rates of vaccination. For example, immunization pharmacies in all 50 U.S. states allow patients to receive immunizations without a physician's order or prescription [47] , enabling patients to have much more autonomy in receiving vaccination than ever before. While such efforts might improve vaccination use for the general population, the relative timing and contraindications of some vaccines during some types of DMARD and biologic therapies argue for the involvement of the rheumatologist in guiding such decisions.
In conclusion, vaccination remains an important strategy for infection-related risk reduction in rheumatology patients, many of whom are at higher risk for vaccine-preventable infections. RA patients should receive annual influenza vaccine, as well as pneumococcal vaccination in accordance to new guidance from the CDC. While zoster vaccination contains live virus, and it is contraindicated during biologic therapy, the high rates of zoster among RA and other subsets of rheumatology patients raises the importance of greater frequency of use of this vaccine prior to biologic therapy initiation. Further research should aim to evaluate the safety and effectiveness of this and other vaccines specifically within the RA setting.
